RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a 'Sector Perform' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $100.
September 13, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital's reiteration of a 'Sector Perform' rating and a $100 price target on Biomarin Pharmaceutical could influence investor sentiment.
Analyst ratings and price targets can significantly influence investor sentiment and trading behavior. In this case, RBC Capital's reiteration of a 'Sector Perform' rating and a $100 price target on Biomarin Pharmaceutical (BMRN) could potentially impact the stock's performance in the short term. However, as this is a reiteration and not a change, the impact may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100